HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
HPPI receives three tranche preferred stock and warrant funding, with $2.4 million upfront, $1.6 million by mid-2018, and an additional $1 million by year end if BCCNS NDA is acceptedHPPI's Supply...
Page (1) of 1 - 01/11/18||
(January 11, 2018)
This article is no longer available,but here are some related topics.
USA, Inc.,Science,Communications Technology,Medical,Cancer,Business,Other,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved